127 related articles for article (PubMed ID: 32564486)
1. Distinct T-cell receptor profiles associated with hepatitis B e antigen seroconversion during entecavir treatment.
Lian YF; Xu Y; Gu YR; Bi YH; Liao CH; Zhao MX; Liao XL; Wang ZH; Wu HK; Huang YH
Liver Int; 2020 Nov; 40(11):2672-2684. PubMed ID: 32564486
[TBL] [Abstract][Full Text] [Related]
2. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
3. The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4(+)CD25(+) regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment.
Yang J; Sheng G; Xiao D; Shi H; Wu W; Lu H; Cao H; Li L
Cell Mol Immunol; 2016 Sep; 13(5):678-87. PubMed ID: 26899927
[TBL] [Abstract][Full Text] [Related]
4. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Serum IFN- and IL-5 Levels in Response to Entecavir Therapy in Patients with Chronic Hepatitis B Virus Infection.
Badary TM; ElBadawy O; Agban MN; Kamel S; Sadek A
Egypt J Immunol; 2018 Jan; 25(1):93-103. PubMed ID: 30243001
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
7. Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy.
Xu Y; Liu Y; Zhao M; Chen Y; Xie C; Gong M; Deng H; Li X; Sun J; Hou J; Wu H; Wang Z
Front Immunol; 2017; 8():1142. PubMed ID: 28959264
[TBL] [Abstract][Full Text] [Related]
8. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
9. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
[TBL] [Abstract][Full Text] [Related]
11. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
[TBL] [Abstract][Full Text] [Related]
13. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Chang TT; Lai CL; Kew Yoon S; Lee SS; Coelho HS; Carrilho FJ; Poordad F; Halota W; Horsmans Y; Tsai N; Zhang H; Tenney DJ; Tamez R; Iloeje U
Hepatology; 2010 Feb; 51(2):422-30. PubMed ID: 20049753
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
15. Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment.
Yang J; Guo R; Yan D; Lu H; Zhang H; Ye P; Jin L; Diao H; Li L
Front Cell Infect Microbiol; 2020; 10():335. PubMed ID: 32793509
[TBL] [Abstract][Full Text] [Related]
16. Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response.
Lee HW; Kwon JC; Oh IS; Chang HY; Cha YJ; Choi IS; Kim HJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5348-56. PubMed ID: 26100697
[TBL] [Abstract][Full Text] [Related]
17. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
Luo XD; Chen XP; Chen R; Chen XF; Huang J
Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
[TBL] [Abstract][Full Text] [Related]
19. Restricted TcR β chain CDR3 clonotype is associated with resolved acute hepatitis B subjects.
Xiao D; Wang J; Chen Z; Jin X; Xie Y; Yan D; Yang J
BMC Infect Dis; 2021 Jan; 21(1):111. PubMed ID: 33485302
[TBL] [Abstract][Full Text] [Related]
20. [HBsAg seroconversion after entecavir therapy for 7 years following a poor response to interferon-α 2b monotherapy in a HBeAg-negative patient with chronic hepatitis B].
Li TY; Chen YP
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Aug; 36(9):1303-1304. PubMed ID: 27687670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
